BMJ  2005;331:1368 (10 December), doi:10.1136/bmj.38665.534595.55 (published 18 November 2005)

Paper

Time trends in primary resistance to HIV drugs in the United Kingdom: multicentre observational study

Objective To examine whether the level of primary resistance to HIV drugs is increasing in the United Kingdom.

Design Multicentre observational study.

Setting All virology laboratories in the United Kingdom carrying out tests for HIV resistance as part of routine clinical care.

Participants 2357 people infected with HIV who were tested for resistance before receiving antiretroviral therapy.

Main outcome measure Prevalence of drug resistance on basis of the Stanford genotypic interpretation system.

Results Over the study period (February 1996 to May 2003), 335 (14.2%, 95% confidence interval 12.8% to 15.7%) samples had mutations that conferred resistance to one or more antiretroviral drugs (9.3% high level resistance, 5.9% medium level resistance). The prevalence of primary resistance has increased markedly over time, although patterns are specific to drug class; the largest increase was for non-nucleoside reverse transcriptase inhibitors. In 2002-3, the prevalence of resistance to any antiretroviral drug to nucleoside or nucleotide reverse transcriptase inhibitors, to non-nucleoside reverse transcriptase inhibitors, or to protease inhibitors was 19.2% (15.7% to 23.2%), 12.4% (9.5% to 15.9%), 8.1% (5.8% to 11.1%), and 6.6% (4.4% to 9.3%), respectively. The risk of primary resistance was only weakly related to most demographic and clinical factors, including ethnicity and viral subtype.

Conclusions The United Kingdom has one of the highest reported rates of primary resistance to HIV drugs worldwide. Prevalence seems still to be increasing and is high in all demographic subgroups.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    StumbleUpon    Technorati    What's this?

Relevant Articles

Antiretroviral treatment of HIV infected adults

Steven G Deeks
BMJ 2006 332: 1489. [Extract] [Full Text] [PDF]

Resistance to HIV drugs in UK may be lower in some areas

Julie M Fox, Sarah Fidler, and Jonathan Weber
BMJ 2006 332: 179-180. [Extract] [Full Text]

Resistance to HIV drugs is high in the UK
BMJ 2005 331: 0. [Full Text]

Treatment exhaustion of highly active antiretroviral therapy (HAART) among individuals infected with HIV in the United Kingdom: multicentre cohort study

Caroline A Sabin, Teresa Hill, Fiona Lampe, Ryanne Matthias, Sanjay Bhagani, Richard Gilson, Mike S Youle, Margaret A Johnson, Martin Fisher, George Scullard, Philippa Easterbrook, Brian Gazzard, Andrew N Phillips on behalf of the steering committee of the UK Collaborative HIV Cohort Study Group
BMJ 2005 330: 695. [Abstract] [Full Text] [PDF]

Analysis of prevalence of HIV-1 drug resistance in primary infections in the United Kingdom

UK Collaborative Group on Monitoring the Transmission of HIV Drug Resistance
BMJ 2001 322: 1087-1088. [Abstract] [Full Text] [PDF]

This article has been cited by other articles:

• Kemp, D. W., Brown, J. N. (2009). Recent Advances in Pharmacotherapy. Journal of Pharmacy Practice 22: 446-466 [Abstract]  
• Bracciale, L., Colafigli, M., Zazzi, M., Corsi, P., Meraviglia, P., Micheli, V., Maserati, R., Gianotti, N., Penco, G., Setti, M., Di Giambenedetto, S., Butini, L., Vivarelli, A., Trezzi, M., De Luca, A. (2009). Prevalence of transmitted HIV-1 drug resistance in HIV-1-infected patients in Italy: evolution over 12 years and predictors. J Antimicrob Chemother 64: 607-615 [Abstract] [Full text]  
• Hue, S., Gifford, R. J., Dunn, D., Fernhill, E., Pillay, D., on Behalf of the UK Collaborative Group on HIV Dru, (2009). Demonstration of Sustained Drug-Resistant Human Immunodeficiency Virus Type 1 Lineages Circulating among Treatment-Naive Individuals. J. Virol. 83: 2645-2654 [Abstract] [Full text]  
• Mitsuya, Y., Varghese, V., Wang, C., Liu, T. F., Holmes, S. P., Jayakumar, P., Gharizadeh, B., Ronaghi, M., Klein, D., Fessel, W. J., Shafer, R. W. (2008). Minority Human Immunodeficiency Virus Type 1 Variants in Antiretroviral-Naive Persons with Reverse Transcriptase Codon 215 Revertant Mutations. J. Virol. 82: 10747-10755 [Abstract] [Full text]  
• Payne, B. A. I., Nsutebu, E. F., Hunter, E. R., Olarinde, O., Collini, P., Dunbar, J. A. T., Basta, M. S. T., Elston, J. W. T., Schmid, M. L., Thaker, H., Chadwick, D. R. (2008). Low prevalence of transmitted antiretroviral drug resistance in a large UK HIV-1 cohort. J Antimicrob Chemother 62: 464-468 [Abstract] [Full text]  
• Wenning, L. A., Friedman, E. J., Kost, J. T., Breidinger, S. A., Stek, J. E., Lasseter, K. C., Gottesdiener, K. M., Chen, J., Teppler, H., Wagner, J. A., Stone, J. A., Iwamoto, M. (2008). Lack of a Significant Drug Interaction between Raltegravir and Tenofovir. Antimicrob. Agents Chemother. 52: 3253-3258 [Abstract] [Full text]  
• Street, E J, Armstrong, N R, Monteiro, E F, Hale, A D (2008). An audit of baseline HIV-1 genotypic resistance testing in a UK provincial city. Int J STD AIDS 19: 416-417 [Abstract] [Full text]  
• Detsika, M. G., Chandler, B., Khoo, S. H., Winstanley, C., Cane, P., Back, D. J., Owen, A. (2007). Detection and quantification of minority HIV isolates harbouring the D30N mutation by real-time PCR amplification. J Antimicrob Chemother 60: 881-884 [Abstract] [Full text]  
• Sagir, A., Oette, M., Kaiser, R., Daumer, M., Fatkenheuer, G., Rockstroh, J. K., Knechten, H., Schmutz, G., Hower, M., Emmelkamp, J., Pfister, H., Haussinger, D., on behalf of the RESINA Study Team, (2007). Trends of prevalence of primary HIV drug resistance in Germany. J Antimicrob Chemother 60: 843-848 [Abstract] [Full text]  
• Pillay, D. (2007). The priorities for antiviral drug resistance surveillance and research. J Antimicrob Chemother 60: i57-i58 [Abstract] [Full text]  
• Hoffmann, C., Minkah, N., Leipzig, J., Wang, G., Arens, M. Q., Tebas, P., Bushman, F. D. (2007). DNA bar coding and pyrosequencing to identify rare HIV drug resistance mutations. Nucleic Acids Res 35: e91-e91 [Abstract] [Full text]  
• Booth, C. L., Geretti, A. M. (2007). Prevalence and determinants of transmitted antiretroviral drug resistance in HIV-1 infection. J Antimicrob Chemother 59: 1047-1056 [Abstract] [Full text]  
• Booth, C. L., Garcia-Diaz, A. M., Youle, M. S., Johnson, M. A., Phillips, A., Geretti, A. M. (2007). Prevalence and predictors of antiretroviral drug resistance in newly diagnosed HIV-1 infection. J Antimicrob Chemother 59: 517-524 [Abstract] [Full text]  
• Deeks, S. G (2006). Antiretroviral treatment of HIV infected adults.. BMJ 332: 1489-1489 [Full text]  
• Fox, J. M, Fidler, S., Weber, J. (2006). Resistance to HIV drugs in UK may be lower in some areas. BMJ 332: 179-180 [Full text]  

Rapid Responses:

Read all Rapid Responses

HIV-1 drug resistance in primary infections in the UK

Julie M Fox, et al.
bmj.com, 10 Jan 2006 [Full text]

Online poll

Find out more on doc2doc >>